OS Therapies Inc

NYSE American:OSTXUnited States

OS Therapies Incorporated is a clinical-stage biopharmaceutical company. The Company is focused on the identification, development and commercialization of treatments for Osteosarcoma (OS) and other solid tumors. It built a pipeline of product candidates targeting multiple indications for solid cancers. Its pipeline includes two drug technologies: OST-HER2 and OST-tADC. OST-HER2 is an off-the-shelf immunotherapy, which is a type of cancer treatment that helps one’s immune system fight cancer, comprised of a genetically weakened and modified strain of Listeria monocytogenes, a species of bacteria that causes the infection listeriosis, that expresses HER2 peptides. OST-tADC is a tunable ADC with a plug-and-play platform that features tunable pH sensitive silicone linkers (SiLinkers). The payloads can include antibodies, chemotherapeutics, cytotoxins and potentially mRNA treatments directly into and in the vicinity of solid tumors.

Contact Information

Headquarters

15825 Shady Grove Road, Suite 135ROCKVILLE, MD, United States 20850

Phone

410-297-7793

Fax

302-655-5049

Executives

Chairman of the Board, President, Chief Executive Officer

Paul Romness

Chief Financial Officer

Alan Musso

Chief Medical Officer, Chief Scientific Officer

Robert Petit

Independent Director

John Ciccio

Independent Director

Olivier Jarry